This week, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced their “Safe Importation Action Plan.” While patients are rightfully concerned about the affordability of their medicine, the fact remains that there is no way to guarantee the safety of drugs that come into the country from outside the U.S. supply chain.
The biopharmaceutical industry remains committed to ensuring patients have access to the medicines they need, and PhRMA is coming to the table with solutions to lower patients’ out-of-pocket costs at the pharmacy counter. In addition to supporting commonsense policies that lower these out-of-pocket expenses, increase competition in the market, and help level the playing field so that other countries pay their fair share, PhRMA recently launched a new tool to help connect eligible patients with more than 900 public and private assistance programs.
Still, importation schemes will never be the right approach. Not only is importation unworkable and proven dangerous, a recent Reuters article highlights the Canadian government’s rightful and ongoing opposition to importation.
Concerns raised in the article include:
- the lack of Canadian medicine supply which could lead to shortages and increased costs for Canadian patients;
- Canadian regulations that prohibit pharmacists from filling prescriptions written by non-Canadian doctors; and
- the failure of U.S. proposals to properly assess the impact in Canada.
Furthermore, a 2018 update to the 2010 study referenced in the article estimated that, if just 20 percent of U.S. prescription medicines were filled in Canada, the Canadian drug supply would run dry in 183days. Additionally, a recent letter from the Alliance for Safe Online Pharmacies Canada highlighted a host of concerns from Canadian stakeholders.
Our Canadian neighbors have consistently been clear about the fact they have no interest in becoming the medicine cabinet for the United States. That’s part of the reason why we strongly oppose any importation scheme and instead encourage lawmakers to pursue real solutions that will help Americans afford and access their medicines here at home.
Tiffany Haverly
Tiffany Haverly is a former director, public affairs, at PhRMA.
Tiffany Haverly
More oversight needed of unapproved medicines that threaten patients’ health
What they are saying: Florida Drug Importation Program is Unfeasible and Dangerous
Florida’s importation plan puts patients in danger
Three things to know about the accelerated approval pathway
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Why drug importation is bad for Americans
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
What they’re saying: Safety is top concern for recent drug importation proposal
PhRMA responds to Florida’s request for information on drug importation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Look at the facts. Drug importation is dangerous.
Securely dispose of your unwanted medicines on National Take Back Day
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
Resources for understanding the dangers of drug importation
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
"ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals"
Prescription Drug Safety
Drug Importation
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
"ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals"